Last updated: July 24, 2026
Colbenemid’s market presence is limited and structurally exposed to competition from established uricosurics and off-patent generics; the drug’s financial trajectory is constrained by narrow utilization in gout/uric-acid management, constrained prescriber adoption, and low likelihood of new entrants facing meaningful exclusivity barriers outside legacy compounding and older registrations. Publicly available, drug-level sales and exclusivity schedules for COLBENEMID are not provided in this dataset, preventing a quantified revenue trajectory or time-bound commercialization forecast.
What is COLBENEMID, what is it used for, and where does it sit in the gout drug market?
COLBENEMID is an uricosuric agent historically used for the management of hyperuricemia and gout. Commercially, it competes in a crowded therapeutic set where efficacy, dosing convenience, tolerability, and guideline position drive utilization more than price alone.
Therapeutic positioning
- Drug class: uricosuric
- Indication framework (typical historical use): hyperuricemia and gout management
- Competitive set (market structure): xanthine oxidase inhibitors (allopurinol, febuxostat) and other uricosurics (including probenecid where marketed), with corticosteroids/colchicine for flares and anti-IL-1 agents in refractory settings
Market dynamic
- Uricosurics tend to have narrower adoption than xanthine oxidase inhibitors in practice, driven by clinician preference, patient selection constraints, and monitoring requirements.
- In-market volume is usually determined by: (1) guideline alignment, (2) formulary placement, (3) payer reimbursement, and (4) availability and tolerability in real-world populations.
How is COLBENEMID priced and reimbursed, and what market forces determine net sales?
For legacy uricosurics, the economic model is dominated by negotiated price levels, wholesaler contracting, and the degree of generic substitution.
Key drivers of net price
- Generic competition: typically compresses gross-to-net through discounts and rebate pressure
- Reimbursement design: coinsurance and plan formularies drive patient access
- Product availability: supply interruptions and manufacturing continuity affect sustained ordering patterns
Key drivers of net sales volume
- Prescriber switching behavior: uricosurics have lower “default” status versus xanthine oxidase inhibitors
- Patient persistence: efficacy needs and adverse-effect profiles influence continuation
- Targeting: uricosurics require appropriate renal/hepatic patient selection and monitoring, which limits addressable pool
What are the major competitive pressures against COLBENEMID (xanthine oxidase inhibitors vs other uricosurics)?
Competitive pressure is structurally high because colbenemid sits in a therapeutic bucket with multiple entrenched alternatives.
Competitive displacement
- Allopurinol and febuxostat often hold first-line roles for long-term urate lowering due to broad applicability and ease of dosing relative to many uricosuric regimens.
- Probenecid (where available) can compete directly as a uricosuric; competing urate-lowering strategies reduce incremental demand for older uricosurics.
Commercial implication
- COLBENEMID’s revenue floor is generally capped by the addressable patient segment willing and eligible to use a uricosuric, and by the presence of substitutes that are more widely favored in prescribing patterns.
When does COLBENEMID lose exclusivity, and how does that affect launch risk for generics?
A quantified exclusivity timeline and a patent expiration schedule for COLBENEMID are not provided in this dataset, so a time-specific exclusivity loss analysis cannot be completed here.
Practical market impact of exclusivity
- For older small-molecule products, the dominant risk is not exclusivity expiration but patent-free entry and conversion to low-margin generic supply chains.
- For buyers and licensors, the gating factor tends to be regulatory status and market authorization rather than remaining patent life.
What patents protect COLBENEMID, how many are in the estate, and what are the expiration dates?
A complete patent estate listing with numbers, jurisdictions, assignees, and expiration dates is not available in this dataset, so an estate-size and expiration analysis cannot be produced.
What is the Orange Book status of COLBENEMID and what does it imply for generic entry?
Orange Book status details, including listed patents and exclusivity codes for COLBENEMID, are not available in this dataset, so the generic-entry risk assessment cannot be completed.
Which companies are likely to challenge COLBENEMID through Paragraph IV, and what is the litigation landscape?
No COLBENEMID Paragraph IV records, ANDA filings, or Hatch-Waxman litigation identifiers are provided here, so the challenger and litigation landscape cannot be mapped.
What formulation or method-of-use patents could block COLBENEMID generics, and where are the technical barriers?
Formulation, method-of-use, and manufacturing-process patent coverage for COLBENEMID is not provided in this dataset.
General technical/IP barriers for legacy small molecules (high-level)
- If listed patents exist, they typically cluster around formulation parameters (particle size, coatings, excipient systems), stability, and dosing regimens.
- Generic entrants must demonstrate comparability in bioequivalence, and any remaining listed patents can create “skinny label” complexity around specific claims.
How does COLBENEMID compare with probenecid, allopurinol, and febuxostat on market adoption and payer preferences?
A drug-to-drug comparative market share analysis requires sales and reimbursement data not provided here. The market-level dynamic is:
- Allopurinol/febuxostat generally have higher baseline adoption in chronic urate-lowering.
- Uricosurics face a more constrained patient-selection funnel.
- Payers more often place uricosurics based on cost and specific clinical criteria rather than as universal first-line therapy.
What FDA/regulatory status applies to COLBENEMID, and how does it shape commercialization and supply?
FDA regulatory timelines, dosage forms, approval history, and any supply-related actions are not included in this dataset.
Commercial linkage
- Regulatory constraints can limit labeling flexibility, distribution breadth, and switching to alternate strengths or dosage forms.
- If manufacturing is concentrated in a small number of suppliers, supply stability can become a financial driver.
How should investors and licensors underwrite COLBENEMID’s financial trajectory given low visibility on revenues?
Underwriting a legacy, lower-visibility product requires modeling that relies on observable market access rather than growth narratives.
Business-appropriate underwriting lens
- Market access: formulary inclusion and pharmacy channel depth
- Competition: substitution likelihood within urate-lowering categories
- Supply risk: manufacturing capacity and continuity
- IP and regulatory exit ramps: any remaining listed patents, exclusivity, or product-specific regulatory barriers
- Contracting economics: gross-to-net profile, wholesaler fees, and payer rebates
Key takeaways
- COLBENEMID’s market dynamics are dominated by structural competition in urate-lowering therapy, limited addressable patient segments for uricosurics, and generic substitution pressures typical for older small molecules.
- A quantified financial trajectory and time-bound exclusivity/patent roadmap cannot be produced because COLBENEMID-specific Orange Book and patent-lifecycle data are not available in this dataset.
- For commercial decision-making, the most actionable drivers are market access, substitution likelihood within gout/urate-lowering, and supply continuity risk rather than near-term category expansion.
FAQs
- Is COLBENEMID still marketed as a prescription product in the US?
- Does COLBENEMID have any current FDA exclusivity or listed patents that affect generic availability?
- What patient populations are most likely to use COLBENEMID compared with allopurinol and febuxostat?
- How do formulary placements typically influence demand for older uricosurics like COLBENEMID?
- What generic entry scenario is most common for legacy uricosurics once regulatory listings are cleared?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Hatch-Waxman Drug Product Submissions and Related Guidance/Resources. https://www.fda.gov/drugs
- FDA. Drug Approval and Safety Information Databases (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
